Nikolaus (Nik) Fortelny is a Group Leader in Computational Biology at the University of Salzburg, Austria, where he leads the Computational Systems Biology research group within the Department of Biological Sciences & Medical Biology. His research focuses on understanding biological systems at the molecular level through advanced computational approaches. Dr. Fortelny's research interests include: Computational Systems Biology Multi-omics data integration and analysis Single-cell and spatial biology Machine learning applications in biology Network science approaches to biological regulation Immune system modeling His recent publications demonstrate a strong focus on applying computational approaches to understand complex biological systems, particularly in immunology and cellular regulation. His work often involves collaboration with experimental biologists to generate and analyze large-scale datasets from multi-omics experiments collected at single-cell or spatial resolution. Dr. Fortelny is actively involved in research recruitment and is currently hiring for professor positions in Medical Systems Biology and Animal Physiology at the University of Salzburg, with an application deadline of April 19th, 2025. His group regularly seeks students, PhD candidates, postdocs, and staff scientists to join their team.
Lea Atanasova is a Senior Researcher and Principal Investigator at the Institute of Food Technology, Department of Biotechnology and Food Science, University of Natural Resources and Life Sciences Vienna (BOKU). She holds a PhD (Dr. rer. nat.) and a Master’s degree (Mag. rer. nat.) and has extensive postdoctoral experience in fungal molecular biology and genomics. Her research is centered on mycoparasitic fungi such as Trichoderma and Clonostachys , with a focus on carbohydrate-active enzymes, signal transduction, gene expression, and ecological genomics. Her research interests span molecular biology, genetics, genomics, microbiology, mycology, and enzyme technology. She investigates the functional roles of genes and proteins in fungal biocontrol, nutrient acquisition, and host interactions. Her work integrates comparative genomics, transcriptomics, and functional proteomics to understand fungal evolution and ecological niches. The most recent publications highlight a strong trend in understanding fungal signaling pathways (e.g., TOR and MAPK), enzyme diversification (e.g., CDHs, pectate lyases), and the molecular mechanisms of mycoparasitism. Her work also extends to fungal secondary metabolites, host-microbe interactions, and advanced imaging techniques for protein localization. Scientific Awards: Carl Trygger scholarship for research at SLU (Uppsala, Sweden) GSA fungal meeting award, Genetics Society of America (Asilomar, CA, United States) FEMS Young Scientist Meeting Grant, Federation of European Microbiological Societies (Sant Feliu de Guíxols, Spain) Price Award for best Master-/Diploma research, Ecological Society of Germany, Austria and Switzerland (GFÖ) (Bayreuth, Germany) Austria National Park Research Award, Austrian Federal Ministry of Agriculture, Forestry, Environment and Water Management (Vienna, Austria) Ad Futura Special Achievements Fellowship for studies abroad, Slovene human resources development and scholarship fund (Ljubljana, Slovenia) Lea Atanasova has supervised several Master’s and Diploma theses on topics related to fungal biotechnology and enzymology. She leads an Austrian Science Fund (FWF)-funded project on GMC oxidoreductases in Clonostachys rosea . She is actively engaged in the scientific community, serving on editorial boards and as a guest editor. She has organized and chaired sessions at major conferences, including ECFG, and frequently presents her research internationally. She is a key member of the research community at BOKU, contributing to knowledge transfer through student supervision, editorial roles, and conference participation. Her work bridges fundamental fungal biology with applications in agriculture and biotechnology.
**Pernilla Wittung Stafshede** is a Full Professor with Tenure and Head of the Chemical Biology division at Chalmers University of Technology (Gothenburg, Sweden). She previously held professorships at Umeå University (Sweden) and Rice University (USA). Her research focuses on protein folding, metalloproteins, biophysical methods, and applications to diseases like cancer and Parkinson’s. She leads the Wittung-Stafshede Lab , part of Chalmers’ Chemical Biology infrastructure. **Research Interests**: Protein folding mechanisms, metal transfer proteins, spectroscopic techniques, amyloid formation, and biophysical studies of macromolecules. Her work bridges fundamental biochemistry with disease mechanisms, leveraging advanced experimental and computational methods. **Awards**: Notable honors include the Arrhenius Medal (2016), membership in the Swedish Royal Academy of Sciences (2016), and sustained Wallenberg Scholar funding (2010–2022). She is recognized for pioneering contributions to chemical biology. **Key Contributions**: Her lab’s work spans protein dynamics, metallomics, and disease-related protein misfolding. Recent publications highlight systems biology approaches to yeast metabolism and drought stress responses in plants.
Tim Wollesen is an Associate Professor in the Department of Evolutionary Biology at the Faculty of Life Sciences. His research focuses on molluscan evolution, neurogenesis, and developmental genetics, particularly in cephalopods, scaphopods, and chaetognaths. He has led projects funded by the Schrödinger Grant and collaborates internationally on topics like Hox gene expression and single-cell transcriptomics. Research interests include evolutionary developmental biology (evo-devo), comparative genomics, and the molecular mechanisms underlying body plan diversification. Recent studies explore the genetic basis of shell formation, nervous system evolution, and ancestral cell type conservation in spiralians. Notable contributions include analyzing developmental gene expression in squid eyes, sequencing chaetognath transcriptomes, and elucidating Hox gene roles in molluscan body plans. His work bridges molecular biology with evolutionary questions, contributing to UN Sustainable Development Goals through biodiversity research. Received Schrödinger Grant (2018) to support evolutionary research Active in international conferences, presenting on bioadhesives and molluscan cell types Lead researcher on projects like 'Elucidating molluscan evolution by single cell sequencing' (2021–ongoing) His lab focuses on integrative approaches combining genomics, microscopy, and developmental biology to decode evolutionary innovations in invertebrate lineages.
Oscar Kuipers is a Full Professor and Head of the Department of Molecular Genetics at the Groningen Biomolecular Sciences and Biotechnology Institute, University of Groningen, the Netherlands, a position he has held since 1999. He is an internationally recognized leader in antimicrobials, bacterial cell biology, synthetic biology, and bacterial gene regulation. Kuipers also serves as founder and CSO of Omnicin Therapeutics, a company he established in 2019 to develop novel antibiotics for clinical use. Dr. Kuipers earned his PhD in Biochemistry from Utrecht University with research on "Probing the mechanism of pancreatic phospholipase A2 by protein engineering." His early career included positions at NIZO Food Research (1990-1999), where he served as Head of Genetics from 1997-1999, and an EMBO Fellowship in Paris Orsay in 1988. Kuipers' research focuses on several interconnected areas that have significantly advanced our understanding of bacterial systems and antimicrobial development. He is a world-leading expert on lantibiotics (modified antimicrobial peptides produced by bacteria), having unraveled the biosynthesis route of nisin and discovered that nisin induces its own expression through bacterial cell-to-cell signaling. His pioneering work on phenotypic heterogeneity at the single-cell level revealed that differentiation in bacterial cultures is omnipresent and has important implications for bacterial behavior. More recently, Kuipers has developed a synthetic biology suite to mimic non-ribosomally produced peptide antibiotics (NRPS) with ribosomally produced and posttranslationally modified peptides (RiPPs), with applications for developing novel antimicrobials for pharmaceutical use. His publication record demonstrates consistent leadership in antimicrobial research, with particular emphasis on lantibiotics, peptide engineering, and bacterial population dynamics. The research trajectory shows an evolution from fundamental biochemical studies to applied pharmaceutical development, with recent work focusing on overcoming antibiotic resistance through innovative approaches like synthetic helper peptides and hybrid lanthipeptides. Dr. Kuipers has received numerous prestigious honors and awards throughout his career: Chairman of jury to appoint new members to Royal Netherlands Academy of Arts and Sciences (KNAW) (2021) Royal decoration of Knight in the Order of the Dutch Lion by King Willem Alexander (2019) Honorary Professor at Nankai University, China (2019) ISI Thomson Reuters Highly Cited Researcher (2016) Elected Executive Board Member, European Academy of Microbiology (EAM) (2015) Elected Member, European Academy of Microbiology (EAM) (2013) iGEM Team Groningen: European and World Champion 2012 Synthetic Biology (2012) Elected Member, Royal Netherlands Academy of Arts and Sciences (KNAW) (2011) Simon Stevin Meester Award (Science and Technology Award of STW, Dutch Science Council) €500,000 (2011) As supervisor and coordinator of the iGEM team Groningen from 2008-2015, Kuipers mentored numerous students in synthetic biology competitions. His research has been supported by significant funding, including the Simon Stevin Meester Award of €500,000. His work has resulted in an impressive publication record with an h-factor of 113 (Google Scholar) and over 50,000 citations. Kuipers leads research at the Groningen Biomolecular Sciences and Biotechnology Institute, where his group focuses on developing novel antimicrobials for pharmaceutical applications. His recent work has centered on using lantibiotics as templates for new antibiotic development, with his synthetic biology suite enabling the creation of ribosomally produced and posttranslationally modified peptides (RiPPs) as alternatives to non-ribosomally produced peptide antibiotics (NRPS). In 2019, he translated this research into practical applications by founding Omnicin Therapeutics to develop novel antibiotics for clinical use.
Jörg Menche holds a full Professor position (Univ.-Prof.) at the University of Vienna, with dual appointments in the Faculty of Mathematics, Department of Mathematics, and Max Perutz Labs, Department of Structural and Computational Biology. His work bridges mathematical modeling and biomedical research through network-based approaches to complex disease mechanisms. Primary research interests include Network Biology, Computational Systems Medicine, and Immunometabolism, with specific focus on proteomic signatures in neuropathic pain, metabolic reprogramming in obesity, and autoimmunity networks. He develops innovative computational tools like VRNetzer for virtual reality network analysis and BioProfiling.jl for high-content imaging data integration, targeting intersections between metabolism, immunity, and environmental exposures. Recent publications (2019-2024) reveal a dominant trend in multi-omics network medicine, particularly in autoimmunity (AutoCore framework), cardiometabolic diseases, and rare genetic disorders. His work demonstrates exceptional translational impact, with multiple papers highlighted by news outlets and patents (e.g., 3 patents referencing 2021 research). While the text indicates involvement in one project (2016) and 13 activities, grant specifics and student mentoring details remain undisclosed. His collaborative network spans immunology, neuroscience, and toxicology, evidenced by co-authorships with clinical and computational teams. Menche operates within Max Perutz Labs, a premier molecular biology research center in Vienna. His team integrates computational biologists, cell biologists, and clinicians to develop network cartography methods for disease module identification, with strong emphasis on virtual reality interfaces and multi-omics validation.
Barbara Maier is a Principal Investigator at CeMM (Center for Molecular Medicine of the Austrian Academy of Sciences), specializing in tumor immunology and the tumor microenvironment (TME). Her research focuses on immune suppression mechanisms, antigen-presenting cell (APC) dynamics, and T cell exhaustion in cancer, aiming to enhance immunotherapy strategies like immune checkpoint blockade (ICB). Education: Studied molecular biology at the University of Vienna and earned a PhD from MedUni Vienna, investigating type I interferon in pulmonary inflammation under Professor Sylvia Knapp. Barbara Maier’s work explores how tumor-associated APCs and myeloid cells shape T cell responses, using integrative approaches such as single-cell transcriptomics and high-throughput cell culture. Her research addresses critical questions about T cell dysfunction in the TME and draining lymph nodes, with the goal of developing next-generation immunotherapies targeting these pathways. Her recent publications highlight studies on APC subsets in ICB response, spatial T cell exhaustion programs, and myeloid cell-based therapies. She leads the ERC Starting Grant 'REWIRE' (2024–2028) to manipulate lymph node niches for T cell reactivation and an FWF Stand-Alone Project (2024–2027) to enhance T cell immunity in tumor-draining lymph nodes.
Arndt von Haeseler is a Full Professor for Bioinformatics at the Center for Molecular Biology and Department for Computer Sciences at the University of Vienna, as well as at the Department for Medical Biochemistry at the Medical University of Vienna. He serves as the Scientific Director of the Center for Integrative Bioinformatics Vienna (CIBIV) and was previously Dean of the Center of Molecular Biology at the University of Vienna and Head of the Center for Medical Biochemistry at the Medical University of Vienna from 2017-2020. His research focuses on phylogenetic inference, phylogenomics, neural networks, sequence evolution, and complex patterns of evolution. With expertise spanning mathematics, biology, and computer science, he has made significant contributions to computational biology through the development of algorithms and software tools for phylogenetic analysis. His work bridges theoretical approaches with biological applications, particularly in evolutionary biology and genomics. Dr. von Haeseler's recent publications demonstrate a strong trend toward integrating machine learning approaches with traditional phylogenetic methods, while expanding into single-cell RNA sequencing analysis and organoid modeling. His research spans computational methodology development, evolutionary analysis, and biomedical applications, with a consistent focus on improving analytical frameworks for biological sequence data. Visiting Professor at Division of theoretical Genetics, National Institute of Genetics, Mishima, Japan (since 2012) WWTF Science Chair Award, Vienna, Austria (2005) Honorary Professor for Theoretical Biology, University of Leipzig, Germany (since 1999) PhD scholarship, Studienstiftung des Deutschen Volkes, Germany (1985-1988) He mentors numerous PhD students and researchers, including Heiko A. Schmidt, Alina Leuchtenberger, and Cassius Manuel. His laboratory develops computational methods that have found widespread application in evolutionary biology and genomics research. The Center for Integrative Bioinformatics Vienna (CIBIV), which he directs, serves as a hub for interdisciplinary research bridging computational approaches with biological questions.
Susana Chuva de Sousa Lopes is a leading scientist in developmental biology and stem cell research. Currently Professor at the Leiden University Medical Center (LUMC) since 2019, she previously held Associate Professor and Assistant Professor positions there from 2011-2019. She also serves as Guest Professor at Ghent University Hospital's Department of Reproductive Medicine since 2013. Co-discoverer of Epiblast Stem Cells (EpiSC) Developed the KeyGenes machine learning webtool for stem cell differentiation analysis Board member of Stichting Biowetenschappen en Maatschappij (2021-present) Her research focuses on human gametogenesis and ovarian development, with groundbreaking work on the epithelialized epiblast (PICMI) intermediate during embryonic stem cell derivation. She has received prestigious awards including: ERC Consolidator Grant (2017) VICI award (2019) Two Aspasia awards (2006 and 2011) De Snoo-van't Hoogerhuijs Foundation awards Her lab pioneers single-cell analysis of human fetal/adult ovaries and develops artificial follicle systems for fertility preservation. She also explores in vitro gametogenesis and its applications in reproductive toxicology and contraception research.
Professor Alexandra Lusser serves as Professor and Deputy Head in the Department of Molecular Biology at Innsbruck Medical University, where she leads the Chromatin and Epigenetics Laboratory. Her research focuses on understanding the molecular mechanisms of chromatin assembly, remodeling, and epigenetic regulation at both DNA and RNA levels. Professor Lusser completed her PhD at the University of Innsbruck in 1998, followed by postdoctoral training at the University of California, San Diego (2001-2004) in the laboratory of Professor JT Kadonaga. She joined Innsbruck Medical University as Assistant Professor in 2004, achieved her Habilitation for Molecular Biology in 2008, was promoted to Associate Professor, and became a full Professor in 2019. Her research program investigates how eukaryotic DNA is organized in chromatin and how this organization affects DNA metabolism processes including transcription, replication, repair, and recombination. A significant portion of her work examines ATP-dependent chromatin assembly and remodeling mechanisms, variant histone assembly, and epigenetic mechanisms at the mRNA level, particularly mRNA base modifications such as 5-methylcytosine and their roles in mRNA metabolism and translation. Her publications reveal a strong focus on developing and applying innovative biochemical and genomic techniques to study RNA modifications and chromatin dynamics. Professor Lusser's extensive publication record spanning from 1996 to the present demonstrates consistent contributions to the fields of chromatin biology and RNA epigenetics. Her recent work shows particular emphasis on developing novel sequencing methods for RNA modification analysis, exploring the functional consequences of RNA modifications, and investigating the relationship between chromatin remodeling factors and neurological functions. HOECHST Award (1998) APART 3-year postdoctoral fellowship from the Austrian Academy of Sciences (2001) START Prize from the Ministry of Science and Research (2005) Member of the Young Curia of the Austrian Academy of Sciences (2008-2016) Research Award from the State Capital Innsbruck (2009) As Deputy Head of the Department of Molecular Biology, Professor Lusser contributes to departmental leadership while maintaining an active research program. Her laboratory has developed several important methodologies including TUC-Seq for measuring mRNA transcription and degradation rates, bisulfite sequencing for detecting 5-methylcytosine in RNA, and other innovative approaches for studying RNA modifications. Her work bridges molecular biology, biochemistry, and genomics, with implications for understanding fundamental biological processes and potential applications in disease research.
Professor Xin Lu is Director of Research and Full Member at the Ludwig Institute for Cancer Research, Oxford Branch, and Professor of Cancer Biology at the University of Oxford. She has held prominent academic positions since 2007 at Oxford, following professorial roles at University College London (2004-2007) and Imperial College London (2000-2004). As Director of the Oxford Centre for Early Cancer Detection and Cancer Theme co-Lead at the NIHR Oxford Biomedical Research Centre, Professor Lu leads significant research initiatives focused on tumor suppression and cellular plasticity. Professor Lu received her academic training in China and the UK: BSc in Biochemistry from Sichuan University, China (1982) MSc in Cell and Molecular Biology from Cancer Institute, Peking Union Medical College & Chinese Academy of Medical Sciences, Beijing (1985) PhD in Cell and Molecular Biology from Imperial Cancer Research Fund and University College London, London, UK (1991) Professor Lu's research program centers on understanding molecular mechanisms that control cellular plasticity and suppress tumor growth. With a long-standing interest in the tumor suppressor p53 and the ASPP family of proteins, her work has revealed how cells change characteristics in response to external signals - a process fundamental to cancer initiation, metastasis, and therapy resistance. Her laboratory investigates selective transcription mechanisms, regulators of cellular plasticity in gastrointestinal cancers (particularly esophageal and gastric), and the influence of infections like Helicobacter pylori and Epstein-Barr Virus on cell plasticity and cancer development. The discovery of ASPP proteins as key regulators of p53 function represents a major contribution to the field. Analysis of Professor Lu's recent publications shows a consistent focus on cellular plasticity mechanisms, p53 family regulation, and the role of ASPP proteins in cancer and developmental disorders. Her work spans molecular, cellular, and tissue-level investigations, increasingly incorporating advanced techniques like single-cell RNA sequencing and organoid models to study cancer initiation and progression. Professor Lu's significant contributions to science have been recognized with numerous prestigious awards: Fellow of the Royal Society (2020) CDD Award for her work on cell death (2016) Elected Fellow of Academy of Medical Sciences (FMedsci) (2013) Elected Supernumerary Fellow of Magdalen College, University of Oxford (2013) Elected Member of the European Molecular Biology Organisation (EMBO) (2011) Professor Lu has served on numerous scientific advisory boards, grant committees, and editorial boards. She has been a Medical Sciences Division Board Member at the University of Oxford since 2010, serves on the European Research Council (ERC) Consolidator Panel since 2012, and has been a Receiving Editor for Cell Death and Differentiation since 2014. Her leadership extends to organizing major international conferences, including multiple Sino-British Frontier Workshops of Cancer Biology and Ludwig-Nature Conferences on Nuclear Reprogramming of the Cancer Genome. Professor Lu leads a research group at the Ludwig Institute for Cancer Research, Oxford Branch, based at the Old Road Campus Research Building. Her team investigates tumor suppression mechanisms with particular focus on cellular plasticity and selective transcription. The laboratory has made significant contributions to understanding the ASPP family of proteins and their roles in cancer and developmental disorders. Professor Lu's group collaborates extensively with researchers across Oxford University and internationally, particularly with institutions in China.
Satu Mustjoki is a Professor of Translational Hematology at the University of Helsinki (UH), Finland, and holds leadership roles such as Director of the Translational Immunology Research Program (2019–2025) and former Head of the Department at the Helsinki University Hospital (HUS) Comprehensive Cancer Center (2018). She is affiliated with the Faculty of Medicine, UH, and specializes in hematology and immunology. Her research spans somatic mutations in non-malignant diseases, NK cell biology, and personalized medicine. She has led over 20 international grants totaling millions in funding, including ERC Consolidator (€2.047M) and NIH/Academy of Finland collaborations. Education: MD (1997, UH), PhD (2001, UH with distinction), Adjunct Professor (Docent) in Experimental Hematology (2011). Awards include the 2020 City of Helsinki Science Award and ERC Proof-of-Concept grant (2020). Her work bridges clinical and translational research, with focus on immunological biomarkers and cancer immunotherapy. Research emphasizes somatic mutations in autoimmune diseases (e.g., rheumatoid arthritis), T and NK cell dysfunction in blood cancers, and precision medicine strategies. She has supervised 18 completed PhDs and 9 ongoing postdocs, with over 9,900 citations and an H-index of 49. Leadership roles include Scientific Director of the iCAN Digital Precision Cancer Medicine Flagship (2022–2026) and membership in the European Hematology Association’s program committee. Funding highlights include the Academy of Finland Terva Consortium (€830K), EraPerMed EU project (€566K as PI), and industry grants from Pfizer and Novartis. She leads global clinical trials and biomarker programs, contributing to drug discovery and patient stratification strategies in hematologic malignancies.
Dr. Satu Mustjoki is a Professor of Translational Hematology at the Faculty of Medicine, University of Helsinki (UH), Finland. She serves as Director of the Translational Immunology Research Program (2019-2025), Scientific Director of the iCAN Digital Precision Cancer Medicine Flagship (2022-2026), and leads multiple international research consortia including EraPerMed EU and Heal-Art projects. Adjunct Professor (2011), Experimental Hematology, UH Specialist in Clinical Chemistry (2008), UH PhD (2001), UH MD (1997), UH Her research focuses on somatic mutations in hematological malignancies and autoimmune diseases, cancer immunology, and personalized medicine. The work integrates immunogenomics, functional genomics, and clinical translation to identify novel therapy targets and biomarkers. Recent publications highlight somatic mutation analysis in T cells (chronic GVHD, RA), NK cell interactions with blood cancers, and single-cell approaches to melanoma immunotherapy. Key themes include mutation-driven immune dysregulation and precision targeting of apoptotic pathways in leukemia. Helsinki Institute of Life Science (HiLife) Fellow (2017-2025) ERC Consolidator grant awardee (2015-2020) Biomedicum Helsinki award (2018) City of Helsinki Science award (2020) Academy of Finland Senior Research Fellowship (2010-2015) She supervises 9 completed + 9 ongoing post-doctoral researchers, 18 completed + 13 ongoing PhD students, and 22 completed MSc/MD theses. Funding includes major grants from the Erkko Foundation, Leukemia & Lymphoma Society, and Academy of Finland. She participates in European and American hematology scientific committees and leads international clinical studies as principal investigator.
Sigrid Neuhauser is a Full Professor (Univ.-Prof. Mag. Dr.) at the Institute of Microbiology , University of Innsbruck , where she also serves as Deputy Head of the Institute. She is a START-Fellow of the Austrian Science Fund (FWF) and leads a vibrant research group focused on Phytomyxea , phytopathology, and marine and soil microbiology. Education & Career: Current: Professor and Deputy Head, Institute of Microbiology, University of Innsbruck START-Fellow, Austrian Science Fund (FWF) Research Interests: Prof. Neuhauser’s work spans taxonomy and systematics of Phytomyxea , host-parasite interactions , phytopathology , and marine and soil microbiology . Her group uses cutting-edge molecular tools, including transcriptomics and single-cell RNA visualization (FISH), to unravel how biotrophic parasites interact with their hosts at the cellular level. She has pioneered studies on Plasmodiophora brassicae (clubroot) and Maullinia parasites of brown algae, and she leads the EU Marie Curie ITN ALFF – Algal friends and foes . Scientific Awards: START-Fellowship, Austrian Science Fund (FWF) Leadership & Grants: Principal Investigator, HiPhy – Understanding Phytomyxid-Host-Interactions (START-Grant, FWF) Partner, ALFF – Algal friends and foes (EU Marie Curie ITN) Coordinator, YETIS: Yeast Endophytes of VitIS sp. (applied research) Labs & Teams: She heads the Phytomyxea Research Group at the Institute of Microbiology, comprising post-docs, PhD students, and technical staff. The group operates state-of-the-art microscopy, molecular biology, and bioinformatics facilities.
Abdel Rahman Abdel Fattah is a Principal Investigator at CeMM Research Center for Molecular Medicine of the Austrian Academy of Sciences in Vienna, Austria. He previously held a postdoctoral position at CeMM (2022–2024) and KU Leuven (Belgium) (2018–2022). Education: BSc and PhD in Mechanical Engineering from McMaster University (Canada) Current Role: Lab Head at CeMM since 2024 Research Interests focus on multiscale mechanobiology, specifically how cells use mechanical forces and extracellular matrix (ECM) dynamics to coordinate tissue organization. His group combines bioengineered mechanical stimulation tools with advanced imaging and computational models to study: Dynamic Cellular and ECM Interactions in health and disease Mechano-Transcriptomic Mapping using spatial transcriptomics and atomic force microscopy (AFM) Computational Modeling of tissue organization via reaction-diffusion systems and positional information theory Disease Applications: Traumatic brain/spinal cord injuries and liver fibrosis Publications highlight interdisciplinary work across mechanobiology, bioengineering, and vascular pathology, with a focus on magnetic actuation, organoid modeling, and ECM dynamics. Articles appear in Nature Communications , Cell Reports , and Lab on a Chip . Recent studies (2024–2025) explore force-mediated vascular lesion growth and transcriptional hallmarks of aging using single-cell analysis. Technological Innovations include: Magnetic Microactuators for local organoid stimulation 3D Soft Microfluidic Systems for perfused tissues Diamagnetophoresis-Based Bioprinting Single-Cell Transcriptomic Atlases for mechanical stress responders
